We have measured the plasma levels of somatomedin‐C (SM‐C) or insulin‐like growth factor I (IGF‐I) in 13 patients with progressive systemic sclerosis (PSS) and age and sex matched healthy controls. We found the plasma SM‐C levels to be within normal limits in all the patients. Thus, if somatomedin‐C plays a role in the pathogenesis of PSS, it is more likely to be at the fibroblast receptor level or in the synthetic response of fibroblasts to SM‐C.
|Original language||English (US)|
|Number of pages||4|
|Journal||British Journal of Dermatology|
|State||Published - Nov 1988|
ASJC Scopus subject areas